An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy

Cancer Research

Volumn 66, Issue 3, 2006, Pages 1809-1817

  Chamoto, Kenji ^a   Wakita, Daiko ^a   Narita, Yoshinori ^a   Zhang, Yue ^a   Noguchi, Daisuke ^a   Ohnishi, Hideaki ^a   Iguchi, Takeshi ^a   Sakai, Tomoaki ^a   Ikeda, Hiroaki ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; RECOMBINANT ANTIGEN; TETRAMER; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER LOCALIZATION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HELPER CELL; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUMOR; TUMOR REJECTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CELL COMMUNICATION; CELL MOVEMENT; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; THYMOMA; THYMUS NEOPLASMS; TRANSFECTION;

EID: 32944481156     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2246     Document Type: Article

References (42)

1. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-32.
2. Coulie PG, van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol 2003;15:131-7.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
4. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617-27.
5. Chamoto K, Kosaka A, Tsuji T, et al. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci 2003;94:924-8.
6. Ikeda H, Chamoto K, Tsuji T, et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004;95:697-703.
7. Nishimura T, Nakui M, Sato M, et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000;46:552-61.
8. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
9. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
10. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-6.
11. Wang RF. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 2002;188:65-80.
12. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000;165:6047-55.
13. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
14. + anti-tumor T cells requires tumor expression of cell surface MHC class II molecules. Cell Immunol 1997;178:79-90.
15. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci USA 1999;96:8633-8.
16. + T cell-dependent tumor eradication in vivo. J Immunol 2000;165:5495-501.
17. Rennert PD, Hochman PS, Flavell RA, et al. Essential role of lymph nodes in contact hypersensitivity revealed in lymphotoxin-α-deficient mice. J Exp Med 2001;193:1227-38.
18. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23-33.
19. Yoneyama H, Narumi S, Zhang Y, et al. Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J Exp Med 2002;195:1257-66.
20. Stoll S, Delon J, Brotz TM, Germain RN. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 2002;296:1873-6.
21. Miller MJ, Wei SH, Parker I, Cahalan MD. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 2002;296:1869-73.
22. + T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003;4:579-85.
23. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154-9.
24. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004;5:1235-42.
25. + T-cell function in melanoma patients. J Clin Oncol 2003;21:3826-35.
26. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Earth RJ, Jr. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001;61:641-6.
27. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003;198:1023-34.
28. + T cells. J Exp Med 2003;197:985-95.
29. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998;76:34-40.
30. + TCRlo thymocytes in vivo. Science 1990;250:1720-3.
31. Miyawaki S, Nakamura Y, Suzuka H, et al. A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur J Immunol 1994;24:429-34.
32. + thymocytes in vitro. J Immunol 1990;145:4012-7.
33. Givan AL, Fisher JL, Waugh M, Ernstoff MS, Wallace PK. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods 1999;230:99-112.
34. Nishimura T, Burakoff SJ, Herrmann SH. Protein kinase C required for cytotoric T lymphocyte triggering. J Immunol 1987;139:2888-91.
35. Chamoto K, Tsuji T, Funamoto H, et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 2004;64:386-90.
36. Gyobu H, Tsuji T, Suzuki Y, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 2004;64:1490-5.
37. Tsuji T, Yasukawa M, Matsuzaki J, et al. Generation of human tumor-specific, HLA class I-restricted Th1 and Tc1 cells by cell engineering with tumor peptide-specific T cell receptor genes. Blood 2005;106:470-6.
38. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999;59:1071-9.
39. Gunn MD, Kyuwa S, Tarn C, et al. Mice lacking expression of secondary Iymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999;189:451-60.
40. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
41. Fagarasan S, Watanabe N, Honjo T. Generation, expansion, migration and activation of mouse B1 ells. Immunol Rev 2000;176:205-15.
42. Okano F, Merad M, Furumoto K, Engleman EG. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. J Immunol 2005;174:2645-52.